Loading…
ybycmeds was cited for unlawfully selling unapproved and misbranded compounded drugs, specifically semaglutide and tirzepatide products, through its website. The company made false or misleading claims by marketing its compounded products as equivalent to FDA-approved drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Since compounded drugs are not FDA-approved, the marketing claims comparing them to approved products constituted misbranding violations and constituted prohibited introduction of misbranded drugs into interstate commerce.